The humanized anti-sclerostin monoclonal antibody, romosozumab, was first and commercially launched on the Japanese market for the therapy of osteoporosis in patients at high risk of fracture in March 2019 (Amgen Astellas BioPharma Release). This evidence concerns the gene SOST and osteoporosis.